Rigel hit with an­oth­er tri­al set­back as lead drug fos­ta­ma­tinib fails PhII

Rigel’s roller coast­er ride of ad­vances and set­backs con­tin­ued this morn­ing with the news that its drug fos­ta­ma­tinib failed a mid-stage study in IgA nephropa­thy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER